April 15, 2019
Shionogi Announces Data Demonstrating Potent in Vitro Activity of Cefiderocol against the Most Critical Priority Gram-Negative Bacterial Pathogens
Shionogi presented data suggest cefiderocol shows a high potential for treating infections caused by themost difficult to treat Gram-negative (GN) bacteria collected fromacross Europe, including multidrug-resistant strains.